Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With MetMAb Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer.

Trial Profile

Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With MetMAb Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Onartuzumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 01 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 07 Oct 2013 Planned End Date changed from 1 Oct 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 10 Jul 2013 Planned End Date changed from 1 Jun 2018 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top